Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer

Kalkner, Karl Mikael ; Acosta, Stefan LU orcid ; Thorsson, Ola LU ; Frederiksen, Hans LU ; Nilsson, A ; Gustavsson, Bengt ; Elingsbo, Marie ; Stridsberg, M and Abrahamsson, Per-Anders LU (2006) In Prostate Cancer and Prostatic Diseases 9(1). p.92-98
Abstract
In this pilot study, the predictive value of Octreotide scintigraphy (Octreoscan) and/or Chromogranin-A (CgA) was investigated in patients with hormone-refractory prostate cancer treated with Octreotide acetate. In total, 20 patients with progressive disease and bone metastases entered the trial. At baseline Octreoscan, CgA, PSA, alkaline phosphates (ALP) and two self-administered questionnaires (EORTC QLQ C-30 (v3) and brief pain index) were performed and a diary of the pharmaceutical was started. The treatment consisted of Octreotide (Sandostatin LAR) acetate 30 mg intramuscular injection every month. The blood samples and questionnaires were repeated every month until 3 months. Clinical responder was defined as a patient with increased... (More)
In this pilot study, the predictive value of Octreotide scintigraphy (Octreoscan) and/or Chromogranin-A (CgA) was investigated in patients with hormone-refractory prostate cancer treated with Octreotide acetate. In total, 20 patients with progressive disease and bone metastases entered the trial. At baseline Octreoscan, CgA, PSA, alkaline phosphates (ALP) and two self-administered questionnaires (EORTC QLQ C-30 (v3) and brief pain index) were performed and a diary of the pharmaceutical was started. The treatment consisted of Octreotide (Sandostatin LAR) acetate 30 mg intramuscular injection every month. The blood samples and questionnaires were repeated every month until 3 months. Clinical responder was defined as a patient with increased global health score more than 10 units and stable or decreased pain score without an increase in analgesic. In all, 17 patients were treated per protocol, and four were assessed as clinical responders. Six patients developed a reduction in ALP (median -26%, range -5 to -78%). All patients increased in PSA. At baseline, three patients had a negative Octreoscan and the patients with positive lesions, demonstrated uptake of low intensity. At baseline the CgA was elevated above the normal range in 15 of the patients, and during treatment five patients decreased their CgA to the normal range. Neither baseline Octreoscan nor CgA could identify the clinical reponders. A minority of patients improves their health-related quality of life. The decrease and normalization of CgA levels in five patients during therapy indicates therapeutic activity but Octreoscan and CgA could not identify clinical responders. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
somatostatin analog, prostate cancer, neuroendocrine differentiation
in
Prostate Cancer and Prostatic Diseases
volume
9
issue
1
pages
92 - 98
publisher
Nature Publishing Group
external identifiers
  • pmid:16231013
  • wos:000236690300027
  • scopus:33644894779
ISSN
1476-5608
DOI
10.1038/sj.pcan.4500843
language
English
LU publication?
yes
id
f1a3da48-8d2a-41f7-8c4c-19f67abba743 (old id 411353)
date added to LUP
2016-04-01 11:45:46
date last changed
2021-08-11 05:01:04
@article{f1a3da48-8d2a-41f7-8c4c-19f67abba743,
  abstract     = {In this pilot study, the predictive value of Octreotide scintigraphy (Octreoscan) and/or Chromogranin-A (CgA) was investigated in patients with hormone-refractory prostate cancer treated with Octreotide acetate. In total, 20 patients with progressive disease and bone metastases entered the trial. At baseline Octreoscan, CgA, PSA, alkaline phosphates (ALP) and two self-administered questionnaires (EORTC QLQ C-30 (v3) and brief pain index) were performed and a diary of the pharmaceutical was started. The treatment consisted of Octreotide (Sandostatin LAR) acetate 30 mg intramuscular injection every month. The blood samples and questionnaires were repeated every month until 3 months. Clinical responder was defined as a patient with increased global health score more than 10 units and stable or decreased pain score without an increase in analgesic. In all, 17 patients were treated per protocol, and four were assessed as clinical responders. Six patients developed a reduction in ALP (median -26%, range -5 to -78%). All patients increased in PSA. At baseline, three patients had a negative Octreoscan and the patients with positive lesions, demonstrated uptake of low intensity. At baseline the CgA was elevated above the normal range in 15 of the patients, and during treatment five patients decreased their CgA to the normal range. Neither baseline Octreoscan nor CgA could identify the clinical reponders. A minority of patients improves their health-related quality of life. The decrease and normalization of CgA levels in five patients during therapy indicates therapeutic activity but Octreoscan and CgA could not identify clinical responders.},
  author       = {Kalkner, Karl Mikael and Acosta, Stefan and Thorsson, Ola and Frederiksen, Hans and Nilsson, A and Gustavsson, Bengt and Elingsbo, Marie and Stridsberg, M and Abrahamsson, Per-Anders},
  issn         = {1476-5608},
  language     = {eng},
  number       = {1},
  pages        = {92--98},
  publisher    = {Nature Publishing Group},
  series       = {Prostate Cancer and Prostatic Diseases},
  title        = {Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer},
  url          = {http://dx.doi.org/10.1038/sj.pcan.4500843},
  doi          = {10.1038/sj.pcan.4500843},
  volume       = {9},
  year         = {2006},
}